This research aimed to identify the mutational spectrum of the NRAS and AKT1 genes in Egyptian patients with HCC and to assess the impact of these mutations on prognosis and responsiveness to targeted treatment. This evidence concerns the gene NRAS and hepatocellular carcinoma.